Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT04324125 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Start date: March 24, 2020
Phase:
Study type: Observational

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

NCT ID: NCT04323579 Recruiting - Lung Cancer Clinical Trials

Validation of Multiparametric Models and Circulating and Imaging Biomarkers to Improve Lung Cancer EARLY Detection.

CLEARLY
Start date: July 1, 2018
Phase:
Study type: Observational

CLEARLY will focus on validation of a multifactorial "bio-radiomic" protocol for early diagnosis of lung cancer that combines circulating biomarkers and radiomic analysis. It will (a) assess the role of molecular and cellular biomarkers (exosomes, protein signatures, circulating tumor cells - CTCs, microRNA) and radiomic signature, as complementary to assist early detection of lung cancer by low dose computed tomography-LDCT, using bioinformatics techniques; (b) assess the prognostic role of CTCs including the role of cells epithelial mesenchymal transition (EMT) and (c) standardize a method for genomic analysis of CTCs for early detection of treatment resistance.

NCT ID: NCT04322890 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

PIKACHU
Start date: April 16, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

NCT ID: NCT04322617 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

ATHENA
Start date: March 24, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.

NCT ID: NCT04322591 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

POSEIDON
Start date: March 24, 2020
Phase:
Study type: Observational

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.

NCT ID: NCT04322578 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

CONFIRM
Start date: March 24, 2020
Phase: Phase 2
Study type: Interventional

This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer

NCT ID: NCT04321499 Completed - Lungcancer Clinical Trials

SHOX2_PTGER4 DNA Methlyation in Lung Cancer

Epi1
Start date: May 2016
Phase:
Study type: Observational

Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis. In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included. SHOX2 and PTGER4 will be analyzed via PCR.

NCT ID: NCT04318249 Not yet recruiting - Insomnia Clinical Trials

Behavioral Relaxation Approaches for Insomnia in Lung Cancer Patients

LC_ART
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

This is a randomized, 30-day research study that is exploring the effects of two simplified mindfulness interventions in lung cancer patients aimed to improve their sleep quality and anxiety regarding sleep. The investigators will be enrolling a total of 20 patients who have insomnia symptoms. Patients will use a behavioral intervention to help with their sleep.

NCT ID: NCT04317651 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

SPECIALK
Start date: May 16, 2019
Phase:
Study type: Observational

This is a multicenter, observational, retrospective cohort study aimed at assessing the efficacy and safety of crizotinib in ALK positive NSCLC treated in real life setting.

NCT ID: NCT04316364 Recruiting - Clinical trials for Non-Small-Cell Lung Cancer

A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC

Start date: July 14, 2020
Phase: Phase 3
Study type: Interventional

This trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant treatment with monoclonal antibody SHR-1316 or placebo in combination with platinum doublet chemotherapy in participants with resectable Stage II, IIIA, or selected IIIB non-small cell lung cancer (NSCLC) followed by adjuvant SHR-1316 or placebo and monitoring.